What Do More Complex eCRFs Mean for Clinical Research
Applied Clinical Trials
Medidata
What Do More Complex eCRFs Mean for Clinical Research?
This month's blog focuses on the eCRF design complexity metric, which is a score that reflects the relative estimated work effort associated with implementing a clinical study eCRF—including eCRF build, testing, and deployment—using Medidata Rave®.
The formula used to compute eCRF design complexity takes into account the study's total number of unique eCRFs, derivations, simple edit checks, and complex edit checks. The score for a given study is a weighted sum of these four eCRF components, where the weight applied to each component represents relative work effort, consistent with Rave study build resource tracking metrics. As a result, the eCRF design complexity score for a given study should not be taken as an estimate of work effort in actual units (e.g., hours, days, etc.) but as an indicator of relative work effort.
Interestingly, as seen in this month's graph, Phase III data from the Medidata Insights metrics warehouse is in agreement with previous information publicized in other industry sources stating that clinical studies have been steadily growing in complexity over the past decade. Furthermore, it readily follows that more complex protocols (i.e., those having more procedures and assessments per subject) lead to more complex eCRFs.
In a recent Data Analysis blog we revealed that a significant increase in eCRF reuse over the past several years has been accompanied by only modest reductions in eCRF build cycle times. Given the corresponding increase in eCRF design complexity over this time period, these modest gains are more understandable. It is very likely that cycle time (and resource) efficiency gains realized by study teams through reuse are being largely offset by the increasing volume of eCRFs and corresponding edit checks that must be configured for each new study. Organizations may be able to address this issue through focused "data reduction" efforts. First, a more structured approach to protocol design should be considered in which non-essential procedures and assessments can be identified and removed before a protocol is finalized. Second, eCRF standards should be developed that focus on removal of superfluous or non-essential data collection. It is estimated that 15% to 30% percent of data collected during the average clinical trial is never used in a new drug application ("Assessing the Downstream Impact of Protocol Design Complexity," Tufts Center for Study of Drug Development, 2009), so an obvious opportunity presents itself.
As always, Medidata is interested to hear your take on this result. Please also stay tuned as we delve further into the Insights metrics warehouse throughout 2012.
—Medidata Solutions, www.mdsol.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
